Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs?

Summary

Non-steroidal anti-inflammatory agents (NSAIDs) and selective cyclooxygenase (COX-2) inhibitors (coxibs) are commonly used as analgesic and anti-inflammatory agents.Selective COX-2 inhibitors or coxibs were primarily developed asa response to the gastrointestinal toxicity of conventional NSAIDs but may have other side effects. Currently available data suggests definite prothrombotic risk with the coxibs, and the magnitude of risk may vary with individual agents. Based on available data, coxibs should be restricted to use as 2nd-line, possibly as 3rd-line, agents for carefully chosen patients and randomized trials versus placebo or an accepted comparator must be performed to define the overall safety profile in diverse patient populations.The recently announced Prospective Randomized Evaluation of Celecoxib Integrated Safety vs. Ibuprofen or Naproxen (PRECISION) trial will assess the relative cardiovascular safety of three of the most commonly used pain relievers in the treatment of arthritis patients,ibuprofen,naproxen and celecoxib.The study will enroll patients with osteoarthritis, the most common form of arthritis, who have known coronary heart disease or who have multiple risk factors for heart disease and also some patients with rheumatoid arthritis. Patients will be followed for an average of two years to track the occurrence of serious cardiovascular events, including death, heart attack and stroke. This study should provide some definitive evidence of the relative cardiovascular safety of the available anti-inflammatory agents but would be even more useful if it included an arm where patients were treated with analgesics such as acetaminophen and/or moderate strength narcotics.

Keywords

Acute myocardial infarction - coxib - atherothrombosis - cyclooxygenase-2 - prothrombotic

• References

• 1 Abraham NS, Graham DY. NSAIDs and gastrointestinal complications: new clinical challenges. Expert Opin Pharmacother 2005; 06: 2681-9.
• 2 Mukherjee D. Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochem Pharmacol 2002; 63: 817-21.
• 3 Schmedtje Jr JF, Ji YS, Liu WL. et al. Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem 1997; 272: 601-8.
• 4 Belton O, Byrne D, Kearney D. et al. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102: 840-5.
• 5 Shinmura K, Tang XL, Wang Y. et al. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci USA 2000; 97: 10197-202.
• 6 Hennan JK, Huang J, Barrett TD. et al. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 2001; 104: 820-5.
• 7 Dowd NP, Scully M, Adderley SR. et al. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo . J Clin Invest 2001; 108: 585-90.
• 8 Cheng Y, Austin SC, Rocca B. et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002; 296: 539-41.
• 9 Egan KM, Wang M, Fries S. et al. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 2005; 111: 334-42.
• 10 Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. J Am Med Assoc 2001; 286: 954-9.
• 11 Bombardier C, Laine L, Reicin A. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-8 1522p following 1528.
• 12 FDA. Cardiovascular Safety Review of Rofecoxib. Gaithersburg, MD: FDA Advisory Committee; 2001
• 13 FDA. Statistical Reviewer Briefing Document for the Advisory Committee. Gaithersburg, MD; USA: FDA; 2001
• 14 Graham DJ, Campen D, Hui R. et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365: 475-81.
• 15 Bresalier RS, Sandler RS, Quan H. et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-102.
• 16 Bresalier RS, Sandler RS, Quan H. et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma prevention trial Correction. N Engl J Med 2006; 355: 221.
• 17 Nissen SE. Adverse cardiovascular effects of rofecoxib. N Engl J Med 2006; 355: 203-4 author reply 203-5.
• 18 Topol EJ. Failing the public health--rofecoxib, Merck, and the FDA. N Engl J Med 2004; 351: 1707-9.
• 19 Silverstein FE, Faich G, Goldstein JL. et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. J Am Med Assoc 2000; 284: 1247-55.
• 20 Topol EJ. Arthritis medicines and cardiovascular events--”house of coxibs”. J Am Med Assoc 2005; 293: 366-8.
• 21 Topol EJ, Falk GW. A coxib a day won’t keep the doctor away. Lancet 2004; 364: 639-40.
• 22 Ott E, Nussmeier NA, Duke PC. et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003; 125: 1481-92.
• 23 White WB, Strand V, Roberts R. et al. Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. Am J Ther 2004; 11: 244-50.
• 24 FitzGerald G. Valdecoxib meta-analysis signals significant cardiovascular risk. Paper presented at: American Heart Association Scientific Sessions 2004, 2004. New Orleans, LA, USA: 2004
• 25 Furberg CD, Psaty BM, FitzGerald GA. Parecoxib, valdecoxib, and cardiovascular risk. Circulation 2005; 111: 249.
• 26 FDA. Postmarketing Safety Review. Center for Drug Evaluation and Research. Gaithersburg, MD; USA: FDA; 2001.
• 27 Becker RC. COX-2 inhibitors. Tex Heart Inst J 2005; 32: 380-3.
• 28 Catella-Lawson F, Reilly MP, Kapoor SC. et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-17.
• 29 MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 573-4.
• 30 Garcia LARodriguez, Varas-Lorenzo C, Maguire A. et al. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004; 109: 3000-6.